<DOC>
	<DOCNO>NCT00006104</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness trastuzumab plus docetaxel treat woman recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Trastuzumab Plus Docetaxel Treating Women With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate woman HER2-neu overexpressing recurrent metastatic breast cancer treat trastuzumab ( Herceptin ) combination docetaxel . II . Determine toxicity treatment regimen patient . III . Determine duration response treatment regimen patient . IV . Determine time progression patient receive treatment regimen . V. Compare HER2-neu overexpression determine fluorescent situ hybridization ( FISH ) versus immunohistochemistry , correlate finding response treatment regimen patient . VI . Correlate HER2-neu activation immunohistochemistry extracellular domain HER2-neu ELISA response treatment regimen patient . OUTLINE : This multicenter study . Patients receive docetaxel IV 30 minute weekly 6 week plus trastuzumab ( Herceptin ) IV 30-90 minute weekly 8 week . Treatment continue every 8 week absence disease progression unacceptable toxicity . Patients follow monthly 3 month , every 3 month 9 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 18-34 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent metastatic breast cancer HER2neu overexpressing tumor ( 2+ 3+ ) Measurable evaluable disease If bone disease , must lytic lesion No carcinomatous meningitis untreated uncontrolled brain parenchymal disease Prior brain parenchymal disease allow controlled appropriate therapy give least 8 week prior study , patient asymptomatic CNS disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal Alkaline phosphatase great 2.5 time upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No congestive heart failure Ejection fraction great 45 % MUGA No myocardial infarction within past 6 month No ischemic heart disease require medication No uncontrolled hypertension Other : No peripheral neuropathy grade 2 No prior malignancy within past 5 year except curatively treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , contralateral breast cancer No active unresolved infection No history hypersensitivity reaction product contain Polysorbate 80 No poorly control diabetes mellitus Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic response modifier Chemotherapy : Prior adjuvant chemotherapy allow No 1 prior chemotherapy regimen metastatic disease No prior taxane ( docetaxel paclitaxel ) Prior doxorubicin allow total dose less 250 mg/m2 No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy No prior cumulative radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : At least 7 day since prior antibiotic No concurrent investigational drug No concurrent antineoplastic therapy No concurrent parenteral antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>